Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
Roivant Sciences logo
Roivant SciencesROIV
——

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
BioMarin Pharmaceuticals (BMRN) reported accretion (amortization) of discounts and premiums, investments of $455K in Q1 2026.
How has BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 66.6% year-over-year, from $1.36M to $455K.
What is the long-term trend for BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
Over 3 years (2021 to 2025), BioMarin Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a -2.3% compound annual growth rate (CAGR), from -$5.16M to $4.8M.
What does accretion (amortization) of discounts and premiums, investments mean?
Non-cash adjustments to the value of investment holdings.
How do you interpret accretion (amortization) of discounts and premiums, investments?
Reflects the yield profile of the company's treasury and investment portfolio.
How does accretion (amortization) of discounts and premiums, investments compare across companies?
Common for companies with large cash balances invested in fixed-income securities.